title: [Influence of androgen deprivation therapy on bone mineral density in men with prostate cancer].
abstract: OBJECTIVE
  To determine the influence of androgen deprivation therapy (ADT) on bone mineral density (BMD) in men with prostate cancer.
  
  
  METHODS
  Forty-nine men with prostate cancer underwent BMD determination and then were classified into two groups: non-ADT group (21 cases), who were about to receive ADT, and ADT group (28 cases), who had received ADT for more than 1 year. BMD was determined by dual energy X-ray absorptiometry (DEXA) in the lumbar spine (L2-4) and femoral neck in all the patients. The Age-Matched Z scores were used as the reference standard for controlling the difference of age, sex and weight.
  
  
  RESULTS
  Thirteen (62%) of the non-ADT group and 23 (82%) of the ADT group fulfilled the BMD criteria for osteopenia or osteoporosis. Z scores for the Age-Matched control in the lumbar spine and femoral neck were -(0.9 +/- 0.7) and -(0.6 +/- 0.5) in the non-ADT group, and -(1.8 +/- 1.1) and -(1.6 +/- 1.0) in the ADT group, respectively (P<0.01). The men of the ADT group had significantly lower BMD in the lumbar spine and femoral neck than those of the non-ADT group.
  
  
  CONCLUSIONS
  Pre-existing osteopenia and osteoporosis are common in men with prostate cancer before ADT. ADT is significantly associated with the loss of BMD and the evaluation of BMD is necessary before ADT for men with prostate cancer.
authors.affiliation: Department of Urology, the First People's Hospital of Guangzhou, Guangzhou, Guangdong 510180, China. dengjunhong1008@tom.com
authors.forename: Junhong
authors.initials: J
authors.lastname: Deng
authors.forename: Wanqing
authors.initials: W
authors.lastname: Li
authors.forename: Liuping
authors.initials: L
authors.lastname: Yang
authors.forename: Liangsheng
authors.initials: L
authors.lastname: Wang
authors.forename: Dehuan
authors.initials: D
authors.lastname: Zou
mesh_terms: D015502:Absorptiometry, Photon; D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000627:therapeutic use; D015519:Bone Density; D006801:Humans; D008297:Male; D008875:Middle Aged; D009919:Orchiectomy; D010024:Osteoporosis / Q000150:complications* / Q000503:physiopathology; D011471:Prostatic Neoplasms / Q000150:complications / Q000503:physiopathology* / Q000601:surgery*
chemical_list: D000726:Androgen Antagonists